Product Data Sheet

APC/Fire™ 750 anti-human CD304 (Neuropilin-1)

Catalog # / 2372620 / 100 tests

Size: 2372615 / 25 tests

Clone: 12C2

Isotype: Mouse IgG2a, κ

Immunogen: CD304-Fc Fusion protein

Reactivity: Human

Preparation: The antibody was purified by affinity

chromatography and conjugated with

APC/Fire™ 750 under optimal

conditions.


Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and

0.2% (w/v) BSA (origin USA).

Workshop Number: **HCDM** listed

Concentration: Lot-specific



Human peripheral blood mononuclear cells were stained with CD303 PE and CD304 (clone 12C2) APC/Fire™ 750 (top) or mouse IgG2a, κ APC/Fire™ 750 isotype control (bottom).

Applications:

Applications: Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent

staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 μ l per million cells in 100 μ l staining volume or 5 μ l per

100 μl of whole blood.


* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum

emission of 787 nm.

Application Notes:

Clone HA58 recognizes an epitope located in the extracellular D1

domain of CD54.3



Human peripheral blood granulocytes were stained with True-Stain Monocyte Blocker™ (Cat. No. 426103) and Siglec-9 (clone K8) APC/Fire™ 750 (filled histogram) or mouse IgG1, κ isotype control APC/Fire™ 750 (open histogram).

Application References:

- 1. Freeman A, et al. 2014. PLoS One. 9:110928. PubMed
- 2. Johnson P, et al. 2015. Clin Cnacer Res. 21:1321. PubMed

Description:

CD304, also known as neuropilin-1, BDCA-4 and VEGF165R, is a 140 kD type I transmembrane protein. Its extracellular region contains 2 CUB, 2 FV/FVIII, and one MAM domain; a soluble isoform is produced by alternative mRNA splicing. CD304 is involved in angiogenesis, neural development, and tumor metastasis. It's expressed by plasmacytoid dendritic cells, thymocytes, neurons, endothelium, and a subset of T_{FH} cells. CD304 is also expressed in several carcinomas, and a high expression of this molecule in prostate cancer correlates with a poor prognosis.

Antigen References:

- 1. Mizui M and Kikutani H. 2008. Immunity 28:302.
 - Hamerlik P, et al. 2012. J. Exp. Med. 209:507.
 Karjalainen K, et al. 2011. Blood 117:920.
 Lepelletier Y, et al. 2007. P. Natl. Acad. Sci. USA 104:5545.